Navigation Links
Alzheimer's Drug Discovery Foundation Supports Madera Biosciences with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease
Date:8/24/2011

NEW YORK, Aug. 24, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $294,000 to Madera Biosciences, Inc. to develop small molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer's disease.

Madera has identified a series of proprietary compounds that increase the expression of apolipoprotein E (apoE), which has been shown to mediate beta-amyloid clearance from the brain and prevent its accumulation into the plaques that are characteristic of Alzheimer's disease. ApoE is a lipid binding protein that circulates in the blood and the brain and remains the single greatest genetic risk factor for Alzheimer's disease. Increasing the release of apoE from brain cells has actually been shown to decrease beta-amyloid plaques and improve cognitive function in animal models.

Madera's novel, drug-like compounds help to facilitate the release of apoE, aid the beta-amyloid clearance process and are hypothesized to improve symptoms, slow the progression of Alzheimer's disease and potentially reverse the course of the disease. The ADDF's grant will fund Madera's program to optimize these compounds for proof-of-concept testing.

"We are very pleased to work with the ADDF to advance these promising discoveries. The ADDF's support is critical to achieve our goal of providing Alzheimer's patients a therapy that changes the course of the disease," said Rick Jack, Ph.D., Chief Executive Officer for Madera. "These funds will allow us to gain a better understanding of how our compounds affect the pathologies caused by beta-amyloid deposition."

"Madera's unique approach to enhance the secretion apoE holds great promise as a treatment for Alzheimer's disease," said Howard Fillit, MD, Executive Director for the ADDF. "Since apoE is the leading known risk factor for Alzheimer's disease (after aging), developing therapeutics based on our knowledge of apoE biology a is critical challenge in our field."

There are estimated to be more than 5 million patients in the United States and more than 35 million individuals worldwide suffering from Alzheimer's disease. The disease is believed to have an annual impact of $172 billion on health care in the United States and is projected to increase rapidly in the near future.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The Alzheimer's Drug Discovery Foundation (ADDF) is the only nonprofit organization whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries.

About Madera Biosciences (www.maderabiosciences.com)

Madera Biosciences is a biotechnology drug discovery company focusing on Alzheimer's disease and other neurodegenerative diseases. The company was founded in 2008 by Edwin Iwanowicz, Ph.D. and is headquartered in San Diego, CA.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
6. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. FASgen Announces New Discovery for Treatment of Stroke
9. Nobel Prize-Winning Discovery
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces a New Discovery in Obesity Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... September 26, 2017 , ... Data Integrity: , The Key to FDA ... 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity , Consider this situation. ... electronic records may not be trustworthy and reliable … a more detailed evaluation may ...
(Date:9/26/2017)... Milford, PA (PRWEB) , ... September 26, 2017 , ... ... month in Chicago, called “The Magic of Fat,” revealed not only the latest about ... might prove to be an evolution in cosmetic medicine. , “Fat really is magical, ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding ... and overcoming obstacles. “Good Morning Sunshine!: Finding Strength and Comfort in God” is the ... psychology from Fort Hays Sate University, who has worked at a local mental health ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Sonflower Submission”: a ... nature to the inevitable destinations of negativity, complaining and the need to always be ... take effect in order for a lesson in stress-less living to be learned. ...
(Date:9/26/2017)... ... ... out for Daddy is a moving story of a family's unconditional love for each ... for Daddy” is the creation of published author Debra Titus, who has lived in ... her to write this book. , Published by Christian Faith Publishing, Debra Titus’s new ...
Breaking Medicine News(10 mins):